Share on StockTwits

CombiMatrix (NASDAQ:CBMX) CEO Mark D. Mcdonough bought 12,000 shares of CombiMatrix stock in a transaction dated Wednesday, August 27th. The stock was purchased at an average cost of $2.02 per share, for a total transaction of $24,240.00. Following the completion of the transaction, the chief executive officer now directly owns 13,500 shares in the company, valued at approximately $27,270. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

CombiMatrix (NASDAQ:CBMX) traded down 5.58% on Friday, hitting $1.86. 273,253 shares of the company’s stock traded hands. CombiMatrix has a 1-year low of $1.91 and a 1-year high of $4.44. The stock has a 50-day moving average of $2.1 and a 200-day moving average of $2.49. The company’s market cap is $20.6 million.

Separately, analysts at Zacks reiterated an “outperform” rating on shares of CombiMatrix in a research note on Friday, August 8th. They now have a $3.50 price target on the stock.

CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc located in Irvine, California.

Receive News & Ratings for CombiMatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix and related companies with Analyst Ratings Network's FREE daily email newsletter.